Title : Personalized and Precision Medicine PPM as a unique healthcare model through biodesign inspired and biotech driven translational applications and upgraded business marketing to secure the human healthcare and biosafety
Abstract:
Traditionally a disease has been defined by its clinical presentation and observable characteristics, not by the underlying molecular mechanisms, pathways and systems biology-related processes specific to a particular patient (ignoring persons-at-risk). A new systems approach to subclinical and/or diseased states and wellness resulted in a new trend in the healthcare services, namely, personalized and precision medicine (PPM).
To achieve the implementation of PPM concept, it is necessary to create a fundamentally new strategy based upon the biomarkers and targets to have a unique impact for the implementation of PPM model into the daily clinical practice and pharma. In this sense, despite breakthroughs in research that have led to an increased understanding of PPM-based human disease, the translation of discoveries into therapies for patients has not kept pace with medical need. It would be extremely useful to integrate data harvesting from different databanks for applications such as prediction and personalization of further treatment to thus provide more tailored measures for the patients and persons-at-risk resulting in improved outcomes and more cost effective use of the latest health care resources including diagnostic (companion ones), preventive and therapeutic (targeted molecular and cellular) etc.
Translational researchers, bio-designers and manufacturers are beginning to realize the promise of PPM, translating to direct benefit to patients or persons-at-risk. And thus both PPM and nanobiotechnologies are being integrated into diagnostic and therapeutic tools to manage an array of PPM-guided conditions to customize therapeutic management. Novel nanomedicines have been employed in PPM-driven treatment of several diseases, which can be adapted to each patient-specific case according to their genetic profiles. So, partnering and forming strategic alliances between researchers, bio-designers, clinicians, business, regulatory bodies and government can help ensure an optimal development program that leverages the Academia and industry experience and FDA’s new and evolving toolkit to speed our way to getting new tools into the innovative markets.
Healthcare is undergoing a transformation, and it is imperative to leverage new technologies to support the advent of PPM. And it is urgently needed to to discover, to develop and to create new (targeted and/or smart/intelligent) drugs. And with the support of nanotechnology, new targeted therapeutic agents and biomaterials, or aid the development of assays for disease biomarkers and identification of potential biomarker-target-ligand (drug) tandems to be used for the targeting, PPM is making phenomenal steps in the future to come. This is the reason for developing global scientific, clinical, social, and educational projects in the area of PPM and design-driven translational medicine to elicit the content of the new trend. So, the Grand Change and Challenge to secure our Health and Wellness are rooted not in Medicine, and not even in Science! Just imagine WHERE?! In the upgraded Hi-Tech Culture!
Keywords: Personalized & precision medicine, biomarkers, targets, nanoparticles, nanocarriers, nanotheranostics, nanobiomedicine, nanotechnologies
